Inhibition rather than Enhancement of Hemostatic System Activation during Initiation of Oral Anticoagulant Treatment

Summary

Coumarin-induced skin necrosis is believed to be due to a transient hypercoagulable state resulting from a more rapid decline of the protein C activity relative to that of coagulation factors (F) II, IX and X during initiation of oral anticoagulant therapy. We studied hemostatic system activation during early oral anticoagulant treatment with a technique that investigates coagulation activation in the microcirculation.

We determined in 10 healthy volunteers the concentrations of prothrombin fragment F1+2 (f1.2) and thrombin-antithrombin complex (TAT) in blood emerging from an injury of the microvasculature (bleeding time incision) before and after initiation of both high-inten- sity and low-intensity coumarin therapy. In addition, f1.2, TAT, activated F VII (F Vila) and the activities of FII, F VII, F X and protein C were measured in venous blood.

A rapid decline of F VII and protein C was observed in venous blood with activities at 24 h of 7 ± 1% and 43 ± 2%, respectively, during the high-intensity regimen. A 20 to 30% reduction of f1.2 and TAT was seen in venous blood at 72 h with no major difference between the high- and the low-intensity regimen. F Vila levels were substantially affected by anticoagulation with a >90% reduction at 48 h during the high-intensity regimen. Following high-intensity coumarin, a >50% decrease in the fl.2 and TAT levels was found in shed blood at 48 h suggesting substantial inhibition of thrombin generation during early oral anticoagulation. An increase in the f1.2 and TAT levels was seen neither in shed blood nor in venous blood.

Our data do not support the concept of a transient imbalance between generation and inhibition of thrombin as the underlying pathomechanism of coumarin-induced skin nekrosis.

• References

• 1 Comp PC. Coumarin-induced skin necrosis. Drug Safety 1993; 08 (02) 128-135
• 2 D’Angelo SV, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 416-425
• 3 Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diseases. J Clin Invest 1987; 80: 1535-1544
• 4 Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129: 766-768
• 5 Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993; 117: 71-77
• 6 Mannucci PM. Mechanisms, markers and management of coagulation activation. Br Med Bull 1994; 50: 851-870
• 7 Merlini PA, Ardissino D. Laboratory measurement of thrombin activity – what every clinician scientist needs to know. Journal of Thrombosis and Thrombolysis 1995; 2: 85-92
• 8 Kyrle PA, Eichler HG, Jaeger U, Lechner K. Inhibition of prostacyclin and thromboxane A₂generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation 1987; 75: 1025-1029
• 9 Thomgren M, Shari S, Bom GVR. Thromboxane A₂in skin-bleeding time blood and in clotted venous blood before and after administration of acetylsalicylic acid. Lancet 1983; 01: 1075-1078
• 10 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-635
• 11 Gerrard J, Taback S, Singhroy S, Docherty J, Kostolansky I, McNicol A, Kobrinsky M, McKenzie NJ, Rowe R. In vivo measurement of thromboxane B₂and 6-keto-prostaglandin F_lalphain humans in response to a standardized vascular injury and the influence of aspirin. Circulation 1989; 79: 29-38
• 12 Gresele P, Amout J, Deckmyn J, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis – studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-1445
• 13 Nowak J, FitzGerald G. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 1989; 83: 380-385
• 14 Nawroth PP, Stem DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 440-447
• 15 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MAJ. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537
• 16 Miletich J, Sherman L, Broze GJ. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
• 17 Bruhn HD, Liebisch J, Wagner D. Documentation of hypocoagulability by measurement of prothrombin fragment FI+2 when introducing oral anticoagulant therapy. Thromb Res 1992; 68: 317-319
• 18 Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coag Fibrinol 1993; 04: 281-292
• 19 Rao LVM, Rapaport S. Activation of factor VII bound to tissue factor: an early key step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci 1988; 85: 6687-6691
• 20 Bauer KA, Kass BL, ten cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of Factor X activation in humans. Blood 1989; 74: 2007-2015